Misfolding of alpha-synuclein (αSyn) is a central factor in the development of Parkinson’s disease (PD).
In this webinar, Prof. Klaus Gerwert will share groundbreaking research using the immuno-infrared sensor (iRS) – a technology validated in Alzheimer’s disease to directly detect αSyn misfolding in cerebrospinal fluid without seed amplification. He will also reveal promising, unpublished findings from blood serum analysis.
By attending, you will be able to:
- Explain the role of alpha-synuclein misfolding as an early biomarker in Parkinson’s disease.
- Describe how quantum-cascade infrared lasers are used to detect protein misfolding with the immuno-infrared sensor (iRS).
- Discuss the potential of biological diagnostics to enable early and accurate detection of Parkinson’s disease.
Moderator
Dr. Samuel Lockhart
PhD
Dr. Samuel Lockhart, PhD, is a neuroscientist with over 15 years of experience studying late-life brain health through imaging, cognitive, and biomarker research. He has authored more than 80 publications on aging and neurodegenerative disease, co-founded the Wake Forest ADRC Imaging Biomarker Core, and led imaging components of clinical trials aimed at improving brain health. He now provides scientific leadership in developing and implementing imaging biomarker strategies for clinical trials.
Speaker
Prof. Klaus Gerwert
CEO, betaSENSE GmbH
Klaus Gerwert is Professor of Biophysics at Ruhr University Bochum and CEO of betaSENSE GmbH, a RUB spin-off founded in 2020. He also leads the PRODI center for protein diagnostics and has been President of the German Society for Biophysics since 2024. He developed the immuno-IR sensor, which detects protein misfolding via blood test to identify Alzheimer’s risk before symptoms appear. Besides other awards, he received the NRW Innovation Award 2023, endowed with 100,000 euros, for the Alzheimer´s risk biomarker.